Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling
Alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.
Authors
- Joerg F. Hipp (ORCID: https://orcid.org/0000-0002-7875-2988)
- Jan M. Schulz (ORCID: https://orcid.org/0000-0003-1557-5352)
- Thomas Mueggler
- Frédéric Knoflach (ORCID: https://orcid.org/0000-0001-7730-2339)
- Eoin C. O’Connor (ORCID: https://orcid.org/0000-0002-7810-1915)
- Philipp Janz (ORCID: https://orcid.org/0000-0002-6472-2956)
- Philipp Schoenenberger
- Pilar Garcés (ORCID: https://orcid.org/0000-0003-4989-0123)
- Henner Knust
- Basil Künnecke
- Maria‐Clemencia Hernandez (ORCID: https://orcid.org/0000-0003-1621-4188)
- Andreas Bruns (ORCID: https://orcid.org/0000-0001-6965-641X)
- Roger L. Redondo (ORCID: https://orcid.org/0000-0002-3477-689X)
- Daniel Bertrand (ORCID: https://orcid.org/0000-0003-2057-7133)
- Alessandro Brigo (ORCID: https://orcid.org/0000-0001-6860-9515)
- Giuseppe Cecere (ORCID: https://orcid.org/0000-0001-5004-8932)
- Andrés Olivares‐Morales (ORCID: https://orcid.org/0000-0001-9959-0810)
- Michael Honer
- Michael Saxe
- Eric Prinssen
- Theresa M. Ballard
- Barbara Biemans
Institutions
- Roche (Switzerland) (CH)
- HiQScreen (Switzerland) (CH)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.3389/fphar.2025.1626078
- Citations
- 2
- Primary Topic
- Autism Spectrum Disorder Research
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Roche
- F. Hoffmann-La Roche